Alzheimer’s disease is linked to toxic beta-amyloid 42 (Aβ42) clumps in the brain. Designed peptides can bind to Aβ42 to prevent aggregation. Our approach improves this by using a peptide that not only stops clumping but also helps clear Aβ42 through the body’s natural system. We hypothesize that using a nasal ultrasonic nebulizer to deliver the peptide in the mist will allow it to reach the brain quicker. This innovative method offers a more effective and accessible Alzheimer’s treatment.